RxDoctor Payments Data

Vernilyn Juan, MD

Family Medicine · New Orleans, LANPI 1770793911

Payments from drug & device makers

$316in general payments, 2019–2025

Across 12 payments — averaging $26.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$120
  • Novo Nordisk$74
  • AstraZeneca$36
  • Cipher Pharmaceuticals US LLC$21
  • GSK$21
  • Amgen$15
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer1$120
Novo Nordisk4$74
AstraZeneca2$36
Cipher Pharmaceuticals US LLC1$21
GSK1$21
Amgen1$15
Pfizer1$15
Lilly USA, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316 in reported general payments places this provider in the 35th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$44,299
Medicare patients
200
Services billed
488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$114,057
OzempicSemaglutide112$111,934
JardianceEmpagliflozin68$70,726
EliquisApixaban61$52,086
JanuviaSitagliptin Phosphate32$33,635
TradjentaLinagliptin36$32,112
ProliaDenosumab17$29,410
TrulicityDulaglutide16$25,692
MyrbetriqMirabegron21$18,292
LinzessLinaclotide19$17,782
FarxigaDapagliflozin Propanediol24$16,482
XareltoRivaroxaban13$15,514
Repatha SureclickEvolocumab24$12,876
Breo ElliptaFluticasone/Vilanterol13$7,816
SynthroidLevothyroxine Sodium69$5,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$139,749120 claims
Novo NordiskOzempic$74$111,934112 claims
PfizerEliquis, Paxlovid$15$53,51576 claims
AmgenProlia$15$29,41017 claims
AstraZenecaFarxiga$36$16,48224 claims
GSKBreo Ellipta$21$7,81613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →